Supplementary figure2: Inhibition of glycolysis inhibits colony formation and viability in highly malignant cells and sensitizes them to gemcitabine. (A) The highly malignant MIA-PaCa2 and PANC-1 cells and the less malignant BxPc-3 and Capan-2 cells were seeded at a density of 3×105 cells in 6-well tissue culture plates and cultured in a medium with high glucose (25 mmol/L). Seventy-two hours later the cells were trypsinized and 200 MIA-PaCa2 and AsPC-1 or 2000 BxPc-3 or Capan-2 cells/well were seeded in 6-well plates in the presence of a medium with a minimal glucose amount (0.15 mmol/L), or in medium with a high glucose amount (25 mmol/L). Cells were grown without a change of the medium for two weeks, followed by evaluation of fixed and Coomassie-stained colonies consisting of at least 50 cells. The plating efficiency as a percent was calculated using the following formula: 100 × number of colonies/number of seeded cells. (B) MIA-PaCa2, PANC-1 and BxPc-3 cells and the non-malignant immortalized pancreatic ductal CRL 4023 cells, were treated as described in Fig. 2C ; metabolic activity based on NAD(P)H turnover, reflecting viability, was measured by an MTT assay. The control was set to 100%. (C) Cells were treated as described above, and the metabolic activity based on ATP turnover, reflecting viability, was measured with the Cell Titer Glo Assay and analyzed as described above. (D) Cells were pre-treated with 2-deoxy-d-glucose (2-DG, 10 mM). Twenty-four hours later cells were treated with gemcitabine (50 nM, GEM) for additional 72 h -either alone or combined with 2-DG as indicated.
